Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis

Arthritis Rheumatol. 2021 Jun;73(6):1086-1087. doi: 10.1002/art.41645. Epub 2021 Apr 16.

Authors

Ching-Huang Ho¹, Andrea A Silva¹, Jon T Giles², Joan M Bathon², Daniel H Solomon¹, Katherine P Liao¹, I-Cheng Ho¹

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
² Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Validation Study

MeSH terms

Adalimumab / pharmacology*
Adalimumab / therapeutic use
Aged
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / genetics
Biological Assay
Etanercept / pharmacology*
Etanercept / therapeutic use
Humans
Middle Aged
Prognosis
Protein Tyrosine Phosphatase, Non-Receptor Type 22 / drug effects*
Protein Tyrosine Phosphatase, Non-Receptor Type 22 / genetics
Reproducibility of Results
Transcriptome / drug effects*
Treatment Outcome
Tumor Necrosis Factor Inhibitors / pharmacology*
Tumor Necrosis Factor Inhibitors / therapeutic use

Substances

Tumor Necrosis Factor Inhibitors
PTPN22 protein, human
Protein Tyrosine Phosphatase, Non-Receptor Type 22
Adalimumab
Etanercept

Grants and funding